Pancreatic Cancer Research

ResearcherUniversidad San Pablo CEUNo recent work listed

Carlos Plaza

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9911-4814; OpenAlex author ID A5047923852. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: none · 2019: 2 papers · 2020: 1 paper

Papers 10

  1. A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a neoadjuvant strategy of chemoradiation … Co-author DOI 10.1007/s12094-020-02287-w↗
  2. Venous Resection for Locally Advanced Pancreatic Cancer: Time Trend and Outcome Analysis of 65 Consecutive Resections at a High-Volume Center. Co-author DOI 10.1016/j.hpb.2022.05.919↗
  3. Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: A case-series analysis. Last author DOI 10.14701/ahbps.2019.23.2.200↗
  4. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Co-author DOI 10.1007/s12094-016-1594-x↗
  5. Surgery for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12094-017-1688-0↗
  6. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2017.08.003↗
  7. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejso.2016.01.006↗
  8. SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis o… First author DOI 10.1158/1078-0432.ccr-14-3222↗
  9. Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. Co-author DOI 10.1038/bjc.2014.129↗
  10. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/bjc.2013.415↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yolanda Quijano · 7 shared papers, 2013–2020 · strength 0.43
  2. Emilio Vicente · 6 shared papers, 2013–2020 · strength 0.34
  3. Riccardo R.C. Caruso · 4 shared papers, 2016–2019 · strength 0.28
  4. Benedetto Ielpo · 4 shared papers, 2016–2019 · strength 0.28
  5. Antonio Cubillo · 4 shared papers, 2013–2020 · strength 0.21
  6. Manuel M. Hidalgo · 5 shared papers, 2013–2017 · strength 0.20
  7. Rafael Álvarez · 4 shared papers, 2013–2020 · strength 0.20
  8. Hipólito J. Durán · 3 shared papers, 2016–2019 · strength 0.19
  9. Ruth Vera · 2 shared papers, 2017 · strength 0.13
  10. Alfredo Carrato · 2 shared papers, 2017 · strength 0.13
  11. Rafael Álvarez-Gallego · 2 shared papers, 2017 · strength 0.10
  12. E. Barzola · 1 shared paper, 2019 · strength 0.09
  13. Carmen Rubio · 1 shared paper, 2020 · strength 0.09
  14. Xin Chen-Zhao · 1 shared paper, 2020 · strength 0.09
  15. Elena Martín‐Pérez · 1 shared paper, 2017 · strength 0.08
  16. Jesús Rodríguez-Pascual · 2 shared papers, 2013–2014 · strength 0.06
  17. Mariano Barbacid · 2 shared papers, 2013–2014 · strength 0.06
  18. Carmen E. Guerra · 2 shared papers, 2013–2014 · strength 0.06
  19. Antonio Gámez Martínez · 1 shared paper, 2017 · strength 0.04
  20. Alberto Carmona‐Bayonas · 1 shared paper, 2017 · strength 0.04
  21. Enrique de‐Madaria · 1 shared paper, 2017 · strength 0.04
  22. Joaquina Martínez-Galán · 1 shared paper, 2017 · strength 0.04
  23. Mercedes Salgado · 1 shared paper, 2017 · strength 0.04
  24. Berta Laquente · 1 shared paper, 2017 · strength 0.04
  25. P. Jiménez · 1 shared paper, 2017 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.